Opko Health Inc. (NASDAQ:OPK)’s share price traded up 8.3% during trading on Thursday . The stock traded as high as $3.77 and last traded at $3.66. 5,005,393 shares were traded during trading, a decline of 9% from the average session volume of 5,494,411 shares. The stock had previously closed at $3.38.
Several equities analysts have recently commented on the company. BidaskClub raised Opko Health from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 10th. ValuEngine lowered Opko Health from a “sell” rating to a “strong sell” rating in a report on Friday, July 6th. Barrington Research reaffirmed a “buy” rating and set a $7.00 target price on shares of Opko Health in a report on Friday, October 5th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $20.00 target price on shares of Opko Health in a report on Tuesday, August 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. Opko Health has an average rating of “Hold” and an average price target of $9.69.
The company has a quick ratio of 0.90, a current ratio of 1.05 and a debt-to-equity ratio of 0.03.
Opko Health (NASDAQ:OPK) last posted its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.01) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.07) by $0.06. The company had revenue of $263.69 million during the quarter, compared to analyst estimates of $260.37 million. Opko Health had a negative return on equity of 9.32% and a negative net margin of 31.73%. On average, analysts expect that Opko Health Inc. will post -0.23 EPS for the current year.
In related news, CEO Phillip Md Et Al Frost bought 5,000 shares of the stock in a transaction dated Thursday, August 30th. The stock was bought at an average cost of $5.90 per share, with a total value of $29,500.00. Following the completion of the acquisition, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $18,106,810.90. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders have bought 80,000 shares of company stock valued at $447,450 over the last ninety days. Corporate insiders own 42.74% of the company’s stock.
A number of hedge funds have recently modified their holdings of OPK. BlackRock Inc. lifted its position in Opko Health by 38.7% in the second quarter. BlackRock Inc. now owns 29,531,554 shares of the biotechnology company’s stock worth $138,798,000 after purchasing an additional 8,237,434 shares during the period. First Manhattan Co. lifted its position in Opko Health by 4,664.8% in the third quarter. First Manhattan Co. now owns 4,290,713 shares of the biotechnology company’s stock worth $14,845,000 after purchasing an additional 4,200,663 shares during the period. Northern Trust Corp lifted its position in Opko Health by 129.9% in the second quarter. Northern Trust Corp now owns 4,025,496 shares of the biotechnology company’s stock worth $18,920,000 after purchasing an additional 2,274,820 shares during the period. Schwab Charles Investment Management Inc. lifted its position in Opko Health by 49.1% in the second quarter. Schwab Charles Investment Management Inc. now owns 2,395,831 shares of the biotechnology company’s stock worth $11,261,000 after purchasing an additional 788,753 shares during the period. Finally, Canada Pension Plan Investment Board lifted its position in Opko Health by 22.7% in the second quarter. Canada Pension Plan Investment Board now owns 2,263,400 shares of the biotechnology company’s stock worth $10,638,000 after purchasing an additional 418,200 shares during the period. 25.30% of the stock is owned by institutional investors and hedge funds.
Opko Health Company Profile (NASDAQ:OPK)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.
Recommended Story: How is the S&P 500 index different from the DJIA?
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.